Deutsche Bank AG Increases Stake in Prothena Co. plc (NASDAQ:PRTA)

Deutsche Bank AG boosted its position in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) by 195.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 95,970 shares of the biotechnology company's stock after acquiring an additional 63,512 shares during the period. Deutsche Bank AG owned about 0.18% of Prothena worth $1,329,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Virtus ETF Advisers LLC grew its holdings in Prothena by 19.3% during the 4th quarter. Virtus ETF Advisers LLC now owns 5,148 shares of the biotechnology company's stock worth $71,000 after acquiring an additional 833 shares in the last quarter. Headlands Technologies LLC grew its holdings in Prothena by 196.5% during the 4th quarter. Headlands Technologies LLC now owns 7,330 shares of the biotechnology company's stock worth $102,000 after acquiring an additional 4,858 shares in the last quarter. Teacher Retirement System of Texas acquired a new position in Prothena during the 4th quarter worth approximately $145,000. Purkiss Capital Advisors LLC purchased a new stake in shares of Prothena during the 4th quarter worth approximately $149,000. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Prothena by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,409 shares of the biotechnology company's stock worth $158,000 after buying an additional 1,065 shares during the last quarter. Institutional investors and hedge funds own 97.08% of the company's stock.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Piper Sandler reduced their price objective on shares of Prothena from $110.00 to $81.00 and set an "overweight" rating for the company in a research report on Tuesday. Chardan Capital reduced their price objective on shares of Prothena from $40.00 to $18.00 and set a "buy" rating for the company in a research report on Tuesday. Cantor Fitzgerald downgraded shares of Prothena from an "overweight" rating to a "neutral" rating in a research report on Tuesday. Wall Street Zen upgraded shares of Prothena from a "sell" rating to a "hold" rating in a research report on Monday, February 24th. Finally, JMP Securities reduced their price objective on shares of Prothena from $78.00 to $29.00 and set a "market outperform" rating for the company in a research report on Tuesday. Six research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $31.50.

Prothena Trading Down 30.4%

PRTA stock traded down $2.00 on Tuesday, hitting $4.58. The company's stock had a trading volume of 9,647,661 shares, compared to its average volume of 639,104. The firm has a 50 day moving average of $9.54 and a two-hundred day moving average of $12.77. Prothena Co. plc has a 1 year low of $4.46 and a 1 year high of $25.42. The stock has a market cap of $246.53 million, a price-to-earnings ratio of -1.99 and a beta of 0.11.

Prothena (NASDAQ:PRTA - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biotechnology company reported ($1.12) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.20). Prothena had a negative net margin of 90.50% and a negative return on equity of 22.67%. The business had revenue of $2.83 million during the quarter, compared to analysts' expectations of $8.18 million. During the same quarter last year, the company earned ($1.34) EPS. The firm's revenue for the quarter was up 5500.0% compared to the same quarter last year. As a group, equities analysts forecast that Prothena Co. plc will post -4.04 EPS for the current fiscal year.

Prothena Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.